Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Mednet Member

Medical Oncology · Sediman Cancer Center/University Hospitals of Cleveland Case Medical Center

This is a very timely question with the FDA approval of the encorafenib/binimetinib regimen. There are no randomized head-to-head trials comparing BRAF/MEK inhibitors so there are no clear data to guide which regimen is the most effective. The COLUMBUS trial reported the longest OS, PFS with the enc...